Edition:
United States

NuVasive Inc (NUVA.OQ)

NUVA.OQ on NASDAQ Stock Exchange Global Select Market

75.02USD
21 Apr 2017
Change (% chg)

-- (--)
Prev Close
$75.02
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
185,446
52-wk High
$76.24
52-wk Low
$49.91

Latest Key Developments (Source: Significant Developments)

NuVasive announces FDA 510(K) clearance of Coroent small interbody system
Wednesday, 29 Mar 2017 09:00am EDT 

Nuvasive Inc :NuVasive - announced fda 510(K) clearance of coroent small interbody system indicated for intervertebral body fusion at contiguous levels in cervical spine.  Full Article

New evidence-based recommendation released from NICE (U.K.) for lateral interbody fusion
Monday, 20 Mar 2017 09:00am EDT 

Nuvasive Inc : New evidence-based recommendation released from NICE (U.K.) for lateral interbody fusion .NICE stated evidence on efficacy for lateral interbody fusion is adequate in quality and quantity.  Full Article

Nuvasive Q4 non-gaap earnings per share $0.53
Thursday, 9 Feb 2017 04:05pm EST 

Nuvasive Inc : Nuvasive reports fourth quarter and full year 2016 financial results . Q4 non-gaap earnings per share $0.53 . Q4 gaap earnings per share $0.11 . Q4 revenue rose 25.9 percent to $271.1 million . Sees 2017 revenue of $1,065 million . Sees 2017 earnings per share of $1.16 . Sees 2017 non-gaap earnings per share of $2.00 .Fy2017 earnings per share view $2.06, revenue view $1.07 billion -- Thomson Reuters I/B/E/S.  Full Article

Nuvasive sees FY 2017 revenue $1.065 bln
Monday, 9 Jan 2017 08:00am EST 

Nuvasive Inc : Sees fy 2017 revenue $1.065 billion . Sees fy 2016 revenue about $956 million . Nuvasive inc - preliminary full year 2016 non-gaap operating profit margin expected to be in line with guidance of 16.0% . Fy2016 revenue view $952.2 million -- Thomson Reuters I/B/E/S . Fy2017 revenue view $1.07 billion -- Thomson Reuters I/B/E/S .Nuvasive inc - expects full year 2017 non-gaap operating profit margin expansion of approximately 100 basis points compared to full year 2016..  Full Article

NuVasive - sees 2016 revenue of approximately $962 mln
Tuesday, 26 Jul 2016 04:02pm EDT 

NuVasive Inc : FY2016 earnings per share view $1.51, revenue view $936.0 million -- Thomson Reuters I/B/E/S . NuVasive reports second quarter 2016 financial results . Q2 non-GAAP earnings per share $0.40 . Q2 GAAP earnings per share $0.57 . Q2 revenue rose 16.4 percent to $236.2 million . Sees 2016 revenue of approximately $962.0 million . Sees 2016 non-GAAP diluted earnings per share of approximately $1.64 .Sees 2016 non-GAAP operating profit margin of approximately 16.0 pct.  Full Article

Nuvasive agrees to settle patent litigation with Medtronic
Thursday, 30 Jun 2016 04:05pm EDT 

Nuvasive Inc : Nuvasive agrees to settle patent litigation with Medtronic . Nuvasive and Medtronic reached agreement on terms for settlement of previously disclosed patent infringement lawsuits . Company and Medtronic intend to enter into a definitive settlement agreement within 15 days . Reached agreement on terms for withdrawal from proceedings in United States patent and trademark office . After settlement agreement, company will make a one-time payment of $45 million to medtronic .Parties will release each other from any and all liabilities arising out of litigation.  Full Article

NuVasive to acquire Biotronic NeuroNetwork
Monday, 6 Jun 2016 04:05pm EDT 

NuVasive Inc : NuVasive to acquire Biotronic NeuroNetwork . Deal for $98 million . Board of directors of both companies have unanimously approved transaction . Deal immediately accretive to non-GAAP diluted earnings, aligned to operating and EBITDA margin expansion . NuVasive expects to fund acquisition with existing cash on hand .NuVasive expects transaction to be significantly accretive in 2017 and beyond.  Full Article

NuVasive Inc announces proposed offering of $550 million of convertible senior notes due 2021
Wednesday, 9 Mar 2016 04:05pm EST 

NuVasive Inc:Announces proposed offering of $550 million of convertible senior notes due 2021.  Full Article

NuVasive to acquire Ellipse Technologies
Tuesday, 5 Jan 2016 04:15pm EST 

NuVasive Inc :To acquire ellipse technologies.Nuvasive will acquire Ellipse for a $380 million upfront cash payment and a potential $30 million milestone payable in 2017.Expects the acquisition to accelerate its revenue growth toward the high-single digit range.Sees deal to be slightly accretive to the company's non-GAAP diluted earnings per share within the first 12 months.Also expects the transaction to support its five-year, double-digit return on invested capital goal".Nuvasive expects to fund the acquisition with existing cash on hand.  Full Article

NuVasive reaffirms FY 2015 revenue guidance; raises FY 2015 EPS guidance
Tuesday, 27 Oct 2015 04:05pm EDT 

NuVasive Inc:Sees FY 2015 revenue of approximately $810.0 million.Sees FY 2015 GAAP diluted earnings per share of approximately $1.24 compared to GAAP loss per diluted share of $(0.36) for 2014; versus a prior expectation of $1.18 for 2015.Sees FY 2015 Non-GAAP diluted earnings per share of approximately $1.25, an increase of approximately 86.6% compared to non-GAAP diluted earnings of $0.67 for 2014; versus a prior expectation of $1.17 for 2015.FY 2015 revenue of $813 million and EPS of $1.20 - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-NuVasive announces FDA 510(K) clearance of Coroent small interbody system

* NuVasive - announced fda 510(K) clearance of coroent small interbody system indicated for intervertebral body fusion at contiguous levels in cervical spine Source text for Eikon: Further company coverage: